Dec 6 (Reuters) - Molecular diagnostics company BG Medicine Inc cut the estimated price range of its initial public offering of 4.5 million shares to $8 to $10 a share, from $14 to $16 per share, according to a regulatory filing.
Dec 6 (Reuters) - Molecular diagnostics company BG Medicine Inc cut the estimated price range of its initial public offering of 4.5 million shares to $8 to $10 a share, from $14 to $16 per share, according to a regulatory filing.
